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1. Introduction 
Cancer is a molecularly heterogeneous disease [1] and one of the major causes of death 
worldwide. The existence of various types of tumours with different histopathologies, 
genetic and epigenetic variations, and clinical outcomes [2], difficult the understanding of 
this disease, the mechanisms of action of chemotherapeutics and the creation of novel 
therapies.  
The advances in the cancer pathobiology study has its origin on the availability of different 
types of experimental model systems that review the various forms of this disease [2], 
allowing the knowledge of genetics and epigenetics alterations and anticancer drugs testing. 
Studies of cancer rely on the use of primary tumours [1, 3], paraffin-embedded samples [1], 
cancer cell lines [1, 3, 4], xenografts [2, 5, 6], tumour primary cell cultures [3, 4] and/or 
genetically engineered mice [2]. Each of these diverse models are used for different studies, 
mainly because certain types of manipulations for the genetic and DNA methylation 
analysis and drug testing are ethically, and in practice, difficult to perform in animals. Cell 
lines emerge as a feasible alternative to overcome these issues, being at the same time easy 
to manipulate [3] and molecularly characterize (e.g. genetic and/or epigenetically). This cell 
model is exceptional for the fundamental study of the cellular pathways and for disclosing 
critical genes involved in cancer. Nevertheless, a detailed characterization is fundamental 
before its use. This characterization provides important insights about the complexity of the 
polygenetic etiology of cancer and the biological mechanisms involved in this disease [1] 
reinforcing its value as models for its study [1, 7]. Also the characterization of cancer cell 
lines is essential for the development of new anticancer drugs, understanding the action 
mechanisms and the resistance/sensitivity patterns of chemotherapeutics already in use in 
cancer treatment and the development of more targeted anticancer drugs.  
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2. Cancer cell lines as a model for cancer study 
Cancer cell lines have been widely used for research purposes and proved to be a useful tool 
in the genetic approach, and its characterization shows that they are, in fact, an excellent 
model for the study of the biological mechanisms involved in cancer [1]. Examples are 
shown in table 1. The use of cancer cell lines allowed an increment of the information about 
the deregulated genes and signalling pathways in this disease [2, 8]. Furthermore, the use of 
the cell model was in the origin of the development and testing of anticancer drugs 
presently used [8-10], and in the development of new therapies [1, 10, 11], but also as an 
alternative to transplantable animal tumours in chemotherapeutics testing [12]. In fact, the 
use of the appropriate in vitro model in cancer research is crucial for the investigation of 
genetic, epigenetic and cellular pathways [1], for the study of proliferation deregulation, 
apoptosis and cancer progression [2], to define potential molecular markers [3] and for the 
screening and characterization of cancer therapeutics [10, 13]. The results of the research in 
cancer cell lines are usually extrapolated to in vivo human tumours [3] and its importance as 
models for drug testing and translational study have been recognized by many biomedical 
and pharmaceutical companies [8].  
 
Cancer cell line Species  Morphology 
HeLa Homo sapiens Cervix adenocarcinoma Epithelial 
MCF-7 Homo sapiens Breast adenocarcinoma Epithelial 
U87MG Homo sapiens Glioblastoma-astrocytoma Epithelial 
HT-29 Homo sapiens Colon adenocarcinoma Epithelial 
A549 Homo sapiens Lung carcinoma Epithelial 
HEP-G2 Homo sapiens Hepatocellular carcinoma Epithelial 
K-562 Homo sapiens Chronic myeloid leukaemia Lymphoblast 
Cos7 Cercopithecus aethiops SV40 transformed - kidney Fibroblast 
PC3 Homo sapiens Prostate adenocarcinoma Epithelial 
A375 Homo sapiens Malignant melanoma Epithelial 
Table 1. Examples of some widely used cancer cell lines with origin in different cell types. These data 
were obtained from the European Collection of Cell Cultures (ECCC) and American Type Culture 
Collection (ATCC).  
In spite of the essential role of cancer cell lines in biomedical research, there is a debate 
among the scientific community on the fact whether they are or not representative of the 
original tumour [5, 14]. Some authors agree with the idea that there is a high, but not 
perfect, genomic similarity between the original tumour and the cancer cell line derived 
from it [8, 13, 15-17]. Cancer cell lines maintain the tumour-specific chromosome 
abnormalities in the first passages [15], show the same morphologic and molecular 
characteristics of the primary tumour [16] and, in general, maintain the expression of the 
“hallmarks of cancer”, with exception of angiogenesis that requires the presence of stromal 
The Importance of Cancer Cell Lines as in vitro Models in  
Cancer Methylome Analysis and Anticancer Drugs Testing 141 
tissues [8]. As an example, Tomlinson and colleagues (1998) compared a breast primary 
tumour and a cell line originated from that tumour. These authors reported the same BRCA1 
mutation and an identical pattern of allelic loss in multiple loci, indicating that the cell line 
preserves numerous characteristics of the original tumour [17]. Also the data from Finlay 
and Bagulay (1984) demonstrated that the cancer cell lines have a similar response to 
anticancer drugs when compared to the original tumour [18].  
The fact that a large number of long-established cancer cell lines were originated from 
aggressive and metastatic tumours [4, 5], restrict the study of cancer progression and of 
drug therapies development. Cancer cell lines derived from earlier stage and lower grade 
disease seems to be the more promising models. In comparative studies made between 
cancer cell lines derived from earlier stage tumours and the original tumour tissues showed 
good concordance in several parameters, including the state of P53 (100%) and ERBB2 (93%) 
[4]. This shows that this type of cells are more representative of the original tumour [4], 
reflecting more accurately the events that occur in cancer cells in vivo [5].  
While cancer cell lines retain many genetic, epigenetic and gene expression features [3], they 
are genetically more complex than the tumour itself [13]. The differences between cancer cell 
lines and the respective tumours may be explained by the prior selection of initial cells and 
the in vitro Darwinian evolution [3]. Cancer cell lines typically present extensive 
chromosomal rearrangements, oncogene mutations, allelic loss and gene amplifications. 
This can lead to a loss of phenotypic properties and additional molecular changes during 
the cell culturing for long times [14], including modifications in some cellular pathways [3].  
There are numerous reasons for the use of cancer cell lines as an experimental model for the 
study of cancer [2]. They have many intrinsic advantages for cancer research and for new 
therapeutic approaches, increasing their value [8]. Some of the advantages (table 2) of this 
model are listed below: 
- Easiness to handle and manipulate [2-4]. This is an important and, in some cases an 
exclusive characteristic of this model [8]. Cell lines can be genetically/epigenetically 
manipulated using demethylation agents [1, 19], siRNA [20], expression vectors [10] 
and pharmacologically manipulated using cytostatics [13].  
- High homogeneity [2-4]. The heterogeneity of solid tumours difficult their analysis and 
cancer cell lines allow the analysis of a homogeneous population of tumour cells [21]. 
This homogeneity can be seen as a disadvantage because of the natural heterogeneity of 
the tumour. However, this can be overcome using a panel of cancer cell lines 
representative of the heterogeneity observed in the primary tumours [2]. 
- High degree of similarity with the initial tumour [17]. Cancer cell lines are pure 
populations of tumour cells and they represent these cells without the complexity of the 
in vivo environment (stromal and inflammatory cells). This can be seen also as a 
disadvantage [8]. 
- Large number and variety of cancer cell lines available [8], although poorly 
characterized [5].  
- Immediate accessibility to the scientific community [1, 8]. 
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- Unlimited auto-replicative source, in continuous cell lines [4].  
- Easy substitution of contaminated cultures for the respective frozen cell lines [4]. 
- Reproducibility of results in the correct conditions [3]. 
Nevertheless, some disadvantages or limitations (table 2) must be taken into account: 
- Some cell lines may have cross contamination with HeLa cells. A large number of 
cancer cell lines in the cell banks (the most used) have been reported as contaminated 
with HeLa cells [3, 4, 8].   
- Genomic instability [3, 4] which may cause differences between the original tumour and 
the respective cell line [3]. The genotypic and phenotypic drift is more common in 
continuous cultures, especially the ones deposited in cell banks for many years. The 
phenotypic changes can occur by the appearance of subpopulations selected from more 
competitive clones [3, 4]. This can be partially solved (in more recent cancer cell lines) 
limiting the number of passages and using frozen cells with few passages [3].  
- Culture conditions, that can change the morphology, the gene expression and several 
cellular pathways [3].  
- Infections with mycoplasma that can change the culture properties [3]. 
- Difficulty in the establishment of long-term cancer cell lines of certain types of tumours 
[22]. 
- Cell culture environment is different from that of the original tumour [2]. 
- Loss of the natural heterogeneity of the tumour [2]. 
 
Advantages of the use of cancer cell lines Disadvantages of the use of cancer cell lines 
 Easy to handle and manipulate [2-4]. 
 High homogeneity [2-4].  
 High degree of similarity with the 
initial tumour [17].  
 High variety available [8]. 
 Immediate accessibility [1, 8]. 
 Unlimited auto-replicative source [4].  
 Easy substitution [4]. 
 Reproducibility of results [3]. 
 Cross contamination with HeLa cells [3, 
4, 8]. 
 Loss of heterogeneity [2]. 
 Genomic instability [3, 4]. 
 Possibility of modifying the 
characteristics of the cells [3]. 
 Infections with mycoplasma [3]. 
 Difficulty in the establishment of long-
term cancer cell lines [22]. 
 Different environment of the tumour [2]. 
Table 2. Advantages and disadvantages of the use of cancer cell lines as models in cancer research. 
Some of these problems can be solved by the conjugation with other type of models. 
Primary cell cultures (derived directly from the tumours) are a viable tool as they maintain 
some of the heterogeneity of the original tumour. However, the tissue environment is lost 
and some studies cannot be performed in this model, as those that need several passages [3, 
4]. Fresh tumour samples obtained by surgery [3] or tumour samples embedded in paraffin 
[1] can also be used for the study of cancer biology. These models represent the state of the 
tumour in vivo with its heterogeneity, but only at a specific evolutionary moment of the 
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tumour. This sample is limited in amount and the genetic manipulation is almost impossible 
[3]. The xenografts models (nude mice) are used for testing the tumorigenicity and 
metastatic ability of cancer cell lines. They constitute a model for drug testing, providing the 
in vivo microenvironment for human tumour original cells [2, 3]. However, the 
immunocompromised mice have a limitation per se by the important role of inflammation in 
cancer [2, 3]. Animal models, with spontaneous or induced tumours [3], have the advantage 
of providing a historical sequence of the tumour and have been used in the pathobiology 
research of cancer and for testing new therapeutics in vivo. Besides the ethical problem, this 
model also holds the difficulty in extrapolating the data to the human counterpart [22]. 
Another animal model is the genetically engineered mice for cancer that may reproduce 
human in vivo models [3]. This model is important for elucidating the regulatory 
mechanisms of cancer initiation and progression, however it cannot recapitulate all the 
aspects of the cancer [2] and also have limitations regarding genetic manipulation.   
In fact, all the experimental models for cancer research present advantages and 
disadvantages and none of them is completely representative of the phenotype of the 
tumour [2, 3]. Nevertheless, cancer cell lines are adequate models for the research of this 
disease. They provide adequate models for the study of the origin of cancers by the presence 
of initiating cells or cancer stem cells [2, 3] and for drug testing in a first approach [2]. Some 
cancer cell lines can be used for screening RNAi (RNA interference) libraries and other small 
molecules as a way to study interacting pathways in the initiation and survival of the 
tumour [2]. The phenotype and genotype evolutionary study, under selective pressure, can 
be done in cancer cell lines, to understand the cancer progression until metastasis [3]. The 
use of a panel of various subtypes of cancer cell lines increases the importance of this model 
in disclosing the signalling pathways involved in therapeutic response [2]. Cancer cell lines 
are also an excellent tool for the genetic and epigenetic study of cancer, being the genomic 
and methylomic profiling of each cancer cell line crucial for cancer research and their use in 
anticancer drug testing.  
2.1. The importance of the molecular characterization of cancer cell lines 
A cancer cell line is more valuable as an in vitro model for cancer research if it is properly 
molecularly characterized [1, 7]. In Figure 1 this aspect is patent as we can observe an 
increasing of works regarding cell lines characterization which is accompanied by an 
increasing number of papers published concerning the use of cancer cell lines as models for 
cancer research. This type of analysis will allow a more detailed study of the 
genetic/epigenetic events (e.g. disclose critical cancer genes and DNA methylation 
alterations) and cellular pathways associated with oncogenesis [21], in the understanding of 
the microevolutionary progression of the tumour [1] (when the molecular profiling is done 
in different passages [15]) and unveil the molecular patterns associated with 
resistance/sensitivity to anticancer drugs [10, 15]. Specifically, the tumour transcriptional 
profiling and the DNA methylation patterns (i.e. that result in gene expression alterations) can 
be useful as a first approach in the development of new anticancer targeted therapeutics [9].  
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Figure 1. Number of publications regarding: cancer cell lines as models for cancer research (blue line) 
and cancer cell lines characterization (red line). These data were obtained from the papers indexed in 
the free resource PubMed (National Center for Biotechnology Information, at the U.S. National Library 
of Medicine, located at the National Institutes of Health). 
The molecular characterization of cell lines molecular characterization can be done at 
different and complementary platforms - cytogenomic [1, 5, 15], genomic [1, 8], epigenomic 
[1, 15], transcriptomic [1, 13, 23] and proteomic [24]. In addition, the characterization of the 
cells morphology [21, 25], the growth rate by the doubling time measurement [25, 26], the 
growth curve [25] and the tumorigenic capacity in athymic nude mice by transplantation of 
cancer cells to the mice (xenotransplant) [21, 25, 26] should be held. It is also important to 
characterize cancer cell lines regarding their anchorage independency (soft agarose assay) 
[11, 26, 27] that can be significant for studying the interaction of drugs with the cells [28] and 
at their metastatic migration potential and invasiveness capacity, that can be useful for 
determining the genes and pathways involved in metastasis [26, 29].  
The identification and characterization of chromosomal rearrangements allows the detection 
of breakpoints and chromosome abnormalities that can be related with deregulation of 
cancer genes. The characterization of chromosomal instability is also crucial because it can 
be caused by errors in the DNA damage checkpoints, in the DNA repair pathways and in 
the mitotic segregation [1]. 
Also the characterization of DNA amplification is important, as the overexpression of genes 
can be involved in the oncogenic process, as ERBB2 in some types of breast cancer [1] or 
other genes that can be druggable targets like kinases [13].  
Cell lines molecular profiling that disclose alterations in the cell cycle regulators and other 
signalling molecules is important [15, 28] and can be useful for targeting anticancer drugs 
for cell cycle defects. The fact that tumour cells with these alterations are more sensitive to 
anticancer agents highlight the importance of the characterization of cancer cell lines to 
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molecules as P53, RB, MDM-2, CDKs, cyclins, apoptotic regulator proteins [28] and the 
respective genes.  
Recently, Louzada and colleagues (2012) performed a genetic and cytogenetic 
characterization of two rat sister cancer cell lines commercially available, at the levels of 
morphology, ploidy and identification of clonal chromosome rearrangements and 
breakpoint regions. They also analysed the expression profile of two oncogenes and the 
influence of global demethylation in the expression of these genes [1], and realized that 
these two sister cell lines are a good in vitro cell model for Erbb2.  
As referred, the molecular characterization of cancer cell lines is important for anticancer 
drug testing [16], for the definition of chemosensitivity and resistance pattern [10] and their 
correlation with candidate cancer genes [10]. As an example, a research from Hakazaki and 
colleagues (2006) on the characterization of a cancer cell line (FPS-1) derived from an 
undifferentiated pleomorphic sarcoma (UPS) reported upregulation of the Epidermal 
growth factor receptor (EGFR) and cyclooxygenase-2 (COX-2) genes, indicating the use of 
this cell line for the development of drugs that act on these genes or in its cellular pathways 
[16]. Fang and colleagues (2009), when characterizing cell lines derived from malignant 
peripheral nerve sheath tumours (MPNST) from patients with metastatic and recurrent 
disease, identified genes associated with the metastatic potential, indicating some 
therapeutic approaches targeted for these genes [15]. Finally, a pharmacological and 
molecular characterization was made in a panel of 60 different types of human cancer cell 
lines (NCI60) created for the development of anticancer drugs and included DNA, RNA, 
proteins, chromosome and functional profiling, allowing a better interpretation of the 
results of anticancer drug tests [30]. 
The molecular profiling of cancer cell lines also enables an easier assessment of cancer types 
and subtypes, defining which cell lines are more suitable for the different investigations [13], 
which in turn, enhances the screening and study of anticancer drugs. Recently, Kao and 
colleagues (2009) did a characterization of commercially available breast cancer cell lines at 
the gene expression levels and respective gene copy number variation. They were  
able to correlate the cancer cell lines with recognized molecular subtypes of breast  
cancer, concluding which is the most adequate cell line for the study of each tumour 
subtype [13].  
Cancer cell lines must be characterized not only in the first passages, but also during their 
progression, in different passages [15]. The use of cancer cell lines that were characterized 
many years ago [4, 31] and the contamination of the cell lines deposited in cell banks with 
HeLa cells are a problem in cancer research [4, 8] that requires efforts in their molecular 
profiling. The problem of the lack of characterization of cancer cell lines that are used for 
many years [4] was highlighted by Osborne and colleagues (1987) in a study that 
demonstrated that one of the most used breast cancer cell line (MCF-7) showed different 
molecular characteristics according to the lab origin [31]. This fact shows the importance of 
the characterization of these models, that are in cell banks for many years, accumulating, in 
the meantime, a high number of mutations [4, 8]. The existence of a large number of cell 
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lines deposited in cell banks contaminated with HeLa cells, the first established cancer cell 
line, is a serious problem [4, 8] verified after the appearance of molecular methods as DNA 
fingerprinting, that showed cross-contaminations in about 18% of the cell lines deposited in 
the German Cell Line Bank [4, 8, 32]. The generation of databases with the molecular 
characterization of cell lines and with the identification of its contaminants [8] is essential for 
the use of cell lines as credible models. Also the scientific journals, at medium-term, should 
require the profiling of these lines before the publication of any data [4, 8].  
2.2. Methodologies for cancer cell lines molecular profiling 
Several methodologies can be used for a proper molecular characterization of cancer cell 
lines, therefore, the selection and combination of the appropriate methods is essential.  
For the cytogenetic profiling, the study of imbalances or rearrangements at the 
chromosomal level is initially done using G-banding karyotyping [1, 7, 15, 16, 33]. The 
identification of breakpoint regions and/or clonal chromosome rearrangements can be 
further achieved by FISH (Fluorescent in situ Hybridization), usually using chromosome 
painting and BAC/PAC clones [1]. FISH can also be used for the identification of oncogenes 
amplification [1, 34, 35]. Nevertheless, the resolution of such analyses in the detection of 
DNA gains and losses might be increased using CGH (Comparative Genomic 
Hybridization) that allows detecting from 10-20 Mb with metaphase chromosomes down to 
200 bp with high-density array-CGH using BAC or oligonucleotide arrays [5, 15, 34, 36, 37]. 
CGH can be useful in detecting gene imbalances allowing the identification of new 
important genes that can then be up or downregulated in cancer cell lines [34].  
The DNA molecular profiling is possible with the use of DNA fingerprinting [4, 21], RFLP 
(Restriction Fragment Length Polymorphism), probes chromosome-specific [15, 21], STR 
(short tandem repeats) profiling [4] or gene sequencing [36]. Techniques such as RT-qPCR 
(Real-Time Reverse Transcriptase Quantitative PCR) [1, 16, 33, 38, 39], RNA-FISH [1], cDNA 
microarrays and whole genome DNA microarrays [5, 10, 13, 34, 40] can be used for gene 
expression profiling of cancer cell lines. RT-qPCR and RNA-FISH (allows single cell 
analysis) are complementary methods that permit the expression quantification of cancer 
genes [1]. Whole-genome DNA microarrays techniques are useful for the analysis of the 
expression profile genome-wide [10, 13] and copy number variations [13] or for the 
expression analysis of a specific fraction of the genome like promoters, codifying regions, 
SNPs (Single Nucleotide Polymorphisms), spliced exons or a panel of pre-selected genes 
related with specific diseases as cancer. For the study of the protein expression level, the 
most widely used methods are immunohistochemistry [11, 13, 15, 16, 35, 38, 41] and western 
blotting [13, 16]. 
2.2.1. Next generation sequencing technologies in cancer cell lines 
Although the referred methodologies have been successfully used in the characterization of 
cancer cell lines, recently, new promising strategies for analysis of genetic and epigenetic 
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alterations have emerged, providing a large amount of information at low cost. These are 
based in Next Generation Sequencing (NGS), which allows the sequencing of almost all 
coding regions (and at a low-extension, non-coding sequences) of both the genome and the 
methylome [42, 43]. The NGS platforms have the power of sequencing massively-parallel 
short-read DNA [42] with a high-throughput at a low cost [44], substituting some techniques 
as the Sanger traditional sequencing [45] and microarrays [42]. Incredibly, NGS can produce 
up to 1 billion of sequences per instrument in four days. However, these results are highly 
dependent on the analysis with refined bioinformatics programs, and the large amount of 
information makes the data treatment sometimes difficult [42, 45]. 
NGS is responsible for the recent increase of epigenetic studies, transforming the resolution 
of the characterization at the epigenetic level [42, 43, 46], and have allowed the construction 
of the first map of the human methylome [43]. The genome-wide DNA methylation 
profiling can be done by array-based or sequencing-based (NGS) with the combination of 
bisulfite conversion (that transforms the unmethylated cytosines into uracil, preserving the 
methylated cytosines) or immunoprecipitation of the methylated DNA (MeDIP) [42, 47]. The 
single-nucleotide resolution of these platforms provides information about the methylation 
of each cytosine, which is an important mark in oncogenesis. An example of the use of 
genome-wide DNA methylation immunoprecipitation-sequencing for the methylome 
profiling in cancer cell lines was made recently by Ruike and colleagues (2010) and their 
data indicate breast cancer cell lines as being globally hypomethylated and with numerous 
hypermethylated sequences [48]. For the study of epigenetics genome-wide, a technology 
that combines chromatin-immunoprecipitation (ChIP) and NGS technologies has been used 
[42]. The ChIP methodology is based on DNA and proteins interactions and together with 
NGS platforms (ChIP-Seq) is used to analyse histones’ modifications genome-wide, as 
methylation [42,43].  
The development of high-throughput DNA sequencing and whole-genome platforms for 
the analysis of the transcriptome, methylome, microRNAs and copy number changes is 
essential for the advance in cancer cell lines profiling. While the use of these platforms for 
cancer cell lines profiling is only at the beginning, these techniques have already proved its 
value in the identification of copy number alterations, mutations detection or different 
methylation patterns of genes [8].  
3. Methylome analysis in cancer 
Besides the genetic alterations (as point mutations, deletions, translocations or 
amplifications), it is now settled that imbalances in the DNA methylation patterns are key 
processes in tumour formation and progression [1, 49]. Thus, the profiling of cancer cell line 
models must also be done at the epigenetic level, and more particularly, at the DNA 
methylation level [5], that leads to heritable alterations of gene expression that do not 
involve alterations in the sequence of DNA [5, 50, 51]. As can be observed in Figure 2, the 
methylation analysis in cancer cell lines is still very scarce. 
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Figure 2. Number of publications regarding cancer cell lines characterization at the DNA methylation 
level (green line). These data were obtained from the papers indexed in the free resource PubMed 
(National Center for Biotechnology Information, at the U.S. National Library of Medicine, located at the 
National Institutes of Health).  
The methylation of DNA is a chemical modification catalyzed by DNA methyltransferases 
(DNMT1, DNMT3A, DNMT3B) [51-53], involving the covalent addiction of a methyl group 
(CH3) to the carbon in the 5-position of the cytosine ring [50-52], normally in a CpG 
dinucleotide context. CpG dinucleotide can be grouped in CpG islands in the promoter 
region of the genes [50, 53].  
DNA methylation plays a crucial role in several epigenetic events of normal cells, as 
genomic imprinting, X chromosome inactivation, retroelement silencing, etc [53], being at 
the same time important in DNA repair, genomic stability and in the regulation of 
chromatin structure [50].  
Recently, the role of DNA methylation in cancer has been an important subject of research 
[47, 51, 54], because we are now aware that the disruption of the methylome is an important 
hallmark of the oncogenic process [54], both the initiation and progression [47]. Depending 
on the pattern of the modification, the genome damage can result in the (over)expression or 
silencing of a gene [51, 53], predisposing cells to cancer [51]. The aberrant methylation can 
begin early in tumorigenesis and can induce most of the pathways modifications in cancer, 
as loss of cell cycle control and apoptosis signalling, alteration of transcription factors 
function, disruption of cell-cell or cell-substratum interaction, among others [55]. This 
deregulation can affect different types of genes as tumour suppressor genes, oncogenes and 
cancer-associated viral genes [50]. The cancer genome is characterized by a global genomic 
hypomethylation and a dense hypermethylation of CpG islands in the regulator regions of 
genes [50, 51, 54].  
DNA hypermethylation is the most studied epigenetic alteration in cancer [51]. It can be 
important as a tool for cancer diagnostic, as a biomarker of malignant cells, as a prognostic 
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factor [49, 54], and it may represent a good target for future therapy [54]. When aberrant 
methylation occurs in the promoter region of tumour suppressor genes, it may lead to its 
silencing [50, 51, 56] and loss of protein function [1]. Thus, the role of aberrant 
hypermethylation in cancer is easily understood for the transcriptional silencing of 
important genes in the cancer prevention [49]. The methylation profile is different for 
different types of tumours, suggesting specificity [54, 56]. However, it is unknown how this 
framework acts to “decide” which genes and when are they methylated [51, 56]. This 
profiling can be vital for the premature detection of cancer in sensitive and specific 
methylation markers and for the identification of important pathways as therapeutic targets 
[56]. The hypermethylation profiling was already done in different types of tumours, in 
cancer cell lines (table 3) and in fresh tumours leading to the identification of methylated 
genes cancer-specific and in different types of cancer [56]. A high concordance was observed 
between the fresh tumours and the respective cell lines, making them good models for the 
study of cancer methylome. Hypermethylation can influence the development and 
preservation of a cell-specific phenotype for the specific silencing of gene sets [5]. The genes 
that are most susceptible to hypermethylation include genes involved in all the cellular 
pathways [54]: in cell cycle regulation (P16INK4a [51, 52, 54, 56], P15INK4a [51, 53], PRB [51, 
52], P14ARF [51, 54]), in DNA repair (MLH1 [53, 54] BRCA1 [47, 51, 54, 56], MGMT [51, 52, 
54]), in apoptosis (APAF-1 [53, 54], DAPK [51, 54]), and in differentiation, angiogenesis, 
metastasis and drug resistance [51]. For instance, the hypermethylation can affect the 
P16INK4α/PRB/CDK4 pathway by the hypermethylation of P16INK4a which is an inhibitor 
of the cell cycle, allowing the cell to escape from cellular senescence and continue to 
proliferate [54]. There are other genes that have shown to be hypermethylated across 
different types of cancer as RASSF1A (tumour suppressor gene Ras association domain 
family member 1) [47, 51, 56-58] and P16INK4a (cyclin-dependent kinase inhibitor) [51, 52, 
56, 59-61] and genes that are hypermethylated in specific types of cancers, such as GSTP1 
that is methylated in 90% of prostate cancer but unmethylated in other types [51, 56], or 
BRCA1 hypermethylated in breast and ovarian cancers [47, 51, 56, 62], among others.  
 
Gene Methylation 
status in cancer 
Disease Cancer Cell Line Reference 
P16INK4a hypermethylated Variety of cancers 
(e.g. Colon, Breast, 
Renal, Prostate 
and Lung cancers, 
Leukaemia and 
Melanoma) 
Variety of cancer cell 
lines from Colon 
cancer, Breast cancer, 
Renal cancer, Prostate 
cancer, Lung cancer 
Leukaemia and 
Melanoma 
[63, 64] 
RASSF1A hypermethylated Variety of cancers 
(e.g. Leukaemia, 
Colon, Breast, 
Ovarian, Lung, 
Prostate, Renal 
Variety of cancer cell 
lines from 
Leukaemia, Colon 
cancer, Breast cancer, 
Ovarian cancer, Lung 
[57, 58, 
63, 64] 
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Gene Methylation 
status in cancer 
Disease Cancer Cell Line Reference 
and CNS (central 
nervous system) 
cancers and 
Melanoma)  
cancer, Prostate 
cancer, Renal cancer, 
CNS cancer and 
Melanoma.  
P15INK4a hypermethylated Leukaemia, Lung 
and Breast cancers 
Cancer cell lines from 
Leukaemia, Lung 
cancer and Breast 
cancer
[63, 64] 
P14ARF hypermethylated Colon, Breast and 
Renal cancers and 
Leukaemia 
Cancer cell lines from 
Colon cancer, Breast 
cancer, Renal cancer 
and Leukaemia 
[63, 64] 
MLH1 hypermethylated Colon cancer Colon cancer cell lines [63, 64] 
BRCA1 hypermethylated Breast cancer Breast cancer cell 
lines
[65] 
MGMT hypermethylated Leukaemia, 
Colon, Renal, 
Breast and Lung 
cancers and 
Melanoma, CNS 
cancer
Cancer cell lines from 
Leukaemia, Colon 
cancer, Renal cancer, 
Breast cancer, Lung 
cancer, Melanoma 
and CNS cancer 
[63, 64] 
DAPK hypermethylated Leukaemia, Lung, 
Colon, CNS, 
Prostate and 
Breast cancer and 
Melanoma  
Cancer cell lines from 
Leukemia, Lung 
cancer, Colon cancer, 
CNS cancer, Prostate 
cancer, Breast cancer 
and Melanoma
[63, 64] 
GSTP1 hypermethylated Prostate, Breast 
and Lung cancers 
Cancer cell lines from 
Prostate cancer, 
Breast cancer and 
Lung cancer
[64, 66] 
NM23-H1 hypermethylated MPNST MPNST cancer cell 
lines
[15] 
DSC3 hypermethylated Breast cancer Breast cancer cell 
lines
[67] 
MASPIN hypermethylated Breast cancer Breast cancer cell 
lines
[67] 
c-MYC hypomethylated Gastric and Colon 
cancer
Gastric and Colon 
cancer cell lines
[68] 
Table 3. Examples of genes displaying an alterated methylation status in cancer cell lines. 
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The information available about hypermethylation in cancer is much higher than the one 
concerning hypomethylation [51]. However, both conditions may lead to loss of cell cycle 
control and apoptosis signals, change in the function of transcription factors, genomic 
instability, among many other effects [55]. Unlike the hypermethylation, the global 
hypomethylation in cancer occurs more frequently in highly and moderately repeated DNA 
sequences but can also be seen in single-copy sequences [49]. These single copy-sequences 
can be oncogenes, like c-MYC [49, 51, 54] (table 3), and these can be also associated with 
tumour initiation and/or progression [49]. But generally, the global genome 
hypomethylation promotes cancer progression by the induction of chromosome instability 
[51, 54, 56], loss of imprinting [54, 56] and reactivation of transposable elements [51, 54]. 
Thus, the aberrant hypomethylation pattern, which occurs early in tumorigenesis, can be 
also used as a biomarker [49], highlighting the importance of its analysis in cancer cells. 
Unlike the genetic, the methylation modifications are reversible [3, 50], making this event 
excellent for analysis in cancer cell lines and a promising target for therapy. The study of 
DNA methylation in cancer cell lines has been accomplished using demethylating agents, 
such as 5-Azacytidine (5-AZA) and its deoxy derivative 5-Aza-2’deoxycytidine (decitabine), 
that cause global genome demethylation [1, 5, 19, 51, 67]. These demethylating agents are 
used in epigenetic therapy, restoring the hypomethylation state by the inversion of the gene 
silencing induced by hypermethylation [1, 51]. These drugs are based in a cytosine analogue 
that are incorporated in the DNA (decitabine) after phosphorylation or in both the DNA and 
RNA (5-AZA), inhibiting DNMTs (DNA methyltransferases) to methylate the DNA, leading 
to a decrease of the DNA methylation level [51, 53]. Although the numerous studies on 
these demethylating agents, their exact mechanism of action and effects in tumour cells 
remains arguable [1, 52, 69, 70].  
These drugs, used as chemotherapeutic agents in certain types of cancers [50, 52-54, 69], are 
also used to screen for changes in gene expression thought to be regulated by methylation in 
cell lines [1, 5, 15, 53, 54, 56]. These demethylating agents that act as DNMTs inhibitors have 
shown the ability to reactivate epigenetically silenced tumour suppressor genes in cancer 
cell lines. Thus, these drugs can also be used as molecular research tools for the induction of 
DNA demethylation in cancer cell lines [53, 69]. In fact, they have been used in many 
research works for the analysis of the methylation profile before and after cells treatment, 
allowing the identification of epigenetically altered genes [1, 15, 53]. For instance, the 
transcriptional profile of cancer cell lines of esophageal squamous cell carcinoma (ESCC) 
treated with 5-azacytidine allowed the identification of various putative tumour suppressor 
genes that are hypermethylated in these cells [53]. Fang and colleagues (2009) proved that 
the loss of expression of NM23-H1, which is related with metastatic progression, in cell lines 
from MPNST, can be associated with the methylation of CpG islands in the promoter region 
of this gene, making this a reversible process by the use of demethylation agents as 
anticancer drugs [15]. Another study of demethylation in breast cancer cell lines verified the 
transcriptional reactivation of desmocollin 3 (DSC3) and MASPIN, that are tumour 
suppressor genes frequently silenced in breast cancer [67]. Louzada and colleagues (2012), 
alternatively, analysed the effect of decitabine in the expression of two genes in rat breast 
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cancer cell lines and their results showed a decrease of Erbb2 expression (initially 
overexpressed in these cells), showing that this gene is epigenetically regulated [1]. 
Although these demethylation agents are excellent tools for the methylome profiling of 
cancer cell lines, another kind of methylation studies have been done using antisense RNA 
[35, 54] and interference RNA for depleting DNMTs [20, 67].  
The DNA methylation profiling is difficult to perform in the majority of models, but it is 
extremely simple to perform in cancer cell lines, enhancing their value as cell models for the 
study of the methylome and to understand the relationship between the genetic and the 
epigenetic profiles with the effectiveness of anticancer drugs. The use of cancer cell lines as 
models for the methylome analysis was highlighted in a work comparing the transcriptional 
profiling after the treatment with decitabine in in vitro and in vivo revealing similar results, 
what validates the use of this model [53]. Other methylome studies performed in cancer cell 
lines in an epigenome-wide way were performed through the use of recent technologies as 
NGS. In 2010, Ruike and colleagues made a methylation profiling in breast cancer cell lines 
using MeDIP-seq that revealed important insights about the aberrant patterns of DNA 
methylation in these cell lines, allowing a more extensive study about the methylome during 
carcinogenesis and the correlation between the morphological changes and the observed 
methylome alterations [48]. These recent technologies allow the study of the methylome in 
cancer in an unprecedented way [47], but this type of studies are still in the beginning [47].  
The methylome profiling is essential for the early cancer detection, prognostic and treatment 
[50, 51, 55], for the development of new epigenetic therapies [54], for distinguishing tumour 
types and subtypes using molecular biomarkers and predict the chemotherapy response [51, 
54, 55]. But the use of cancer cell lines for the study of DNA methylation alterations in 
cancer is controversial. Although some authors consider it a good model, that have shown 
similar results in the methylome profile when comparing the results in vivo and in vitro [53]; 
there are others, instead, believing that this type of studies should be made in non-cultured 
cells due to the in vitro culture environment [49, 50]. Nevertheless, the problems in the 
association of the epigenetic profiles with cancer, when using other models (difficulties in 
manipulation, sample selection, sample size, data integration, among others [50]), can be, in 
part, solved with the use of cancer cell lines. Thus, it is crucial to analyse the relationship 
between methylation in cancer and the resistance/sensitivity to anticancer drugs in well-
characterized cancer cell lines, making possible the detection of potential drug targets and 
drug resistance markers [47].  
4. Drug testing in cancer cell lines 
Drug testing in cancer cell lines is usually one of the initial steps in drug development. It 
allows the access of a large number of potential drugs before committing to large scale 
expensive in vivo clinical trials. 
The use of cancer cell lines for cytotoxicity evaluation has been made by many researchers 
for many years, having clinical predictive value [2, 18], consistent with the expected from 
the original tumour. Different cancer cell lines display diverse responses to cytotoxic 
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anticancer drugs, as colon cancer cell lines are more resistant to DNA intercalating-drugs 
and breast cancer or leukaemia cell lines are more sensitive [18]. Copeland and colleagues 
(2007) tested the cytotoxicity of an anticancer drug in different prostate cancer cell lines 
derived from prostate cancer subtypes, and confirmed that this drug is more efficient for 
prostate androgen-independent cancer. In this study they proposed this chemotherapeutic 
drug for the treatment of metastatic prostate cancer [71], that should, however, be more 
studied in cancer cell lines for the determination of the action mechanism.  
The testing of anticancer drugs using cancer cell lines over other models presents other 
advantages than just cytotoxicity evaluation tests, because it permits to analyse the action of 
drugs, combinations of them and the screening for resistance/sensitivity [72], with the 
concomitant discovery of specific markers [10]. The identification of epigenetic or genetic 
alterations in specific sequences allows to specifically target the drug in order to achieve a 
therapeutic outcome and identify new potential druggable targets.  
The fact that cancer cells have the oncogenic pathway activated makes these cells less 
dependent of extracellular regulators. Cancer cell lines also have this pathway activated [3], 
retaining the genomic deregulation of transcription of the primary tumour [24], but, at the 
same time, also have a more simple transcriptome by the loss of unneeded functions [3], 
making this one of the best models for anticancer drug testing (single drugs or in 
combination) [2, 3, 6, 10, 18, 24, 71]. This is valid not only in a first approach, but also for 
understanding drugs’ mechanisms of action [10, 73], the resistance/sensitivity of some types 
of cancer to different drugs [10, 24, 72, 74], for the discovery of biomarkers for anticancer 
drugs response (resistance/sensitivity markers) [10, 75, 76], or for the research of signalling 
pathways associated with the therapeutic response [2, 24], among others. Nevertheless, even 
if a cancer cell line comes from the same subtype of tumour, it must be well-characterized 
before its use in anticancer drug testing due to the fact that similar cell lines may present 
different signatures from each other, although retaining the same signature of the original 
tumour [3, 24]. An example are cancer cell lines derived from the same subtype of tumour as 
thyroid papillary carcinomas B-CPAP and TPC-1, displaying different oncogenic pathways 
modified, maintaining that from the original tumour [3]. Others than cancer cell line models, 
will always be needed for the validation of the data, being the clinical trials mandatory 
before the use of any drug in a clinical approach.  
The use of cell line panels is a useful tool for anticancer drug testing. The development of  
these cancer cell lines panels was initiated for the panel NCI60 (panel US National Cancer 
Institute with 60 cancer cell lines) in order to overcome the use of animal models for the test 
of antineoplastic drugs [12]. Afterwards, Nakatsu and colleagues (2005) established a panel 
of 45 cancer cell lines (JFCR-45) from different origins (breast, liver and stomach) to 
determine genes related with chemosensitivity to anticancer drugs. They also tried to 
understand the mechanisms of action of these drugs for their classification. This research, 
that involved an integrated bioinformatic approach using cDNA arrays, revealed many 
candidate genes associated with sensitivity to chemotherapeutic drugs. For the correct 
identification of these genes, they transfected each one in the different cell lines and discover 
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that the overexpression of HSPA1A and JUN genes increased the sensitivity to mitomycin C, 
suggesting that these genes play a role in the response to this anticancer drug. The genes 
discovered in this study can be used as predictive markers of sensitivity to 
chemotherapeutic drugs, which is crucial for a higher effectiveness of the treatment [10]. 
Recently, Garnett and colleagues (2012) screened a panel of several hundred cancer cell lines 
(representing much of the tissue-type and genetic diversity of human cancers) with 130 
drugs under clinical and preclinical investigation and verified that the cancer genes mutated 
are related with the cellular response to the most commonly used drugs, making this 
systematic pharmacogenomic profiling in cancer cell lines a powerful biomarker discovery 
platform to guide rational cancer therapeutic strategies [75]. The use of a cell line panel with 
subtypes of cancer cell lines for studying the signalling pathways involved in the 
therapeutic response was made by Neve and colleagues (2006) that used Herceptin® 
(Trastuzumab) immunotherapy in a system of cancer cell lines ERBB2+, that do not respond 
to this therapy, to identify the molecular signature associated with this phenotype [24]. 
Thus, the use of cancer cell line panels seems to be a powerful system for underlying the 
molecular mechanisms of anticancer drug response [2].  
The existence of databases with detailed genetic and pharmacologic information from 
cancer cell lines allows the generation of genetic predictions of drug response in the 
preclinical setting. An example is Cancer Cell Line Encyclopedia (CCLE, launched by 
Novartis), a database that contains genes’ expression profiling, massively parallel 
sequencing and chromosomal copy number data from almost a thousand human cancer cell 
lines. The integration of the pharmacologic profiles of anticancer drugs with the data from 
the cell lines deposited in CCLE allowed Barrentina and colleagues (2012) to identify 
genetic, lineage, and gene-expression-based predictors of drug sensitivity [76]. However, the 
problem of working with cancer cell lines characterized too many years ago or not 
characterized at all, will definitely difficult data interpretation or even lead to 
misinterpretations.  
The availability of molecular modelling tools, such as QSAR (Quantitative Structure - 
Activity Relationships), giving insights about the molecular interactions of the compounds 
studied with proteins involved in signalling pathways [77], or docking methods that predict 
the strength of association or binding affinity between a drug to a particular target [78], are 
also fundamental tools that should be considered in drug testing studies.  
The characterization of cancer cell lines about the state of cell cycle checkpoints [15, 28], 
regulatory cell cycle proteins [28] and the presence of Multidrug Resistance Domains (MDR) 
[72], are also essential in anticancer drug testing. The effect of anticancer drugs in cancer cell 
lines must be screened on cell cycle progression, checkpoint signalling pathways and cell 
proliferation, making important the characterization of these parameters in cancer cell lines 
before their use as models. For instance, the characterization of several cell lines from head 
and neck squamous cell carcinoma (HNSCC) allowed to disclose that most of them lack the 
checkpoint function by loss of P53 and RB functions and their upstream and downstream 
regulation pathways (e.g. MDM2 and CDK6, respectively) [28]. Cell cycle profiling 
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(progression and checkpoints regulators) of cancer cell lines is thus a valuable tool in the 
development of chemotherapeutic agents as therapeutic targets [28, 79]. In the case of 
antimitotic drugs, the analysis of Microtubules (MTs) and centrosomal proteins [72] should 
also be considered. 
One of the more successful anticancer drug targets are microtubules. These form a highly 
dynamic structure constituted by polymers of α and β-tubulin essential for the development 
and maintenance of cellular morphology, protein trafficking in the cell, cell signalling and 
proper chromosome segregation during mitosis [72, 80]. Their importance in mitosis by their 
mitotic spindle assembly and dynamics required for proper chromosome segregation make 
the microtubules an excellent target for antimitotic therapy [72]. At the moment, three 
different groups of MT-targeted anticancer drugs are widely used for chemotherapy: Vinca 
alkaloids (e.g. vinblastine) [72, 73], taxanes (e.g. paclitaxel - Taxol®) [10, 28, 72] and 
colchicine [72]. These antimitotic drugs bind to different binding sites in β-tubulin, exhibit 
different behaviours and are used for different types of cancer. These drugs act by 
suppression of the MT dynamics, leading to mitotic blocking and cell death by apoptosis 
[72]. However, the exact mechanism of action of these drugs, the resistance/sensitivity 
mechanisms and the combination of these drugs with others is an incomplete research field, 
and cancer cell lines can be excellent models for the study of these drugs as long as they are 
well-characterized.  
Coleman and colleagues (2002) used cancer cell lines from HNSCC for determination of 
the mechanism of action of two drugs combination, paclitaxel and carboplatin. They 
concluded that the paclitaxel activity is related with the increase of cyclin B1/CDC2 
activity, BCL-2 phosphorylation and mitotic block, affecting the cells in mitosis. However, 
their study proved that the efficiency in the inhibition of cell proliferation was higher 
when combining these two drugs, allowing the use of this combination in other models 
[28]. In other work, the sensitivity of tumour cells to paclitaxel in the absence of PLK1 
(polo-like kinase 1) was studied in breast cancer cell lines [81]. PLK1 play a key role in 
different stages of mitosis and its overexpression is a negative prognostic indicator [81, 
82]. The use of antisense oligonucleotides for PLK1 depletion leaded to the conclusion that 
the presence of these antisense oligos increase the response to paclitaxel [81]. Huang and 
colleagues (2004) studied the apoptosis induction of Vinca alkaloids in cancer cell lines. 
The type of analysis performed by these authors, as the use of glucocorticoids to inhibit 
mitotic arrest caused by Vinca alkaloids or transfection with antisense oligonucleotides are 
difficult to perform in other types of models. Moreover, this study revealed another 
signalling pathway (NF-κB/IκB) that might be related with apoptosis induction by this 
antimitotic drug [73].  
As referred, drug resistance is a major problem in cancer chemotherapy [80, 83]. The study 
of the mechanisms that lead to a resistant cell can involve a diversity of molecules. Although 
there is no complete understanding about what leads to cell resistance to certain types of 
drugs, some of them are already known. Multidrug Resistance is a mechanism of drug 
efflux that can be caused by the upregulation of MDR1 gene, leading to an increase of 
membrane transporters as p-glycoprotein (P-GP) [40, 72, 83]. However, it is not completely 
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understood, and the apoptotic pathway also has influence in the resistance to anticancer 
drugs [28, 40, 83]. The resistance to paclitaxel was related with upregulation of antiapoptotic 
BCL-2 family members as BCL-2 e BCL-XL [40]. The resistance of tumour cells to paclitaxel 
and also to other antimitotic drugs can also be attributed to differences in the expression of 
tubulin isotypes, point mutations or post-translational modifications in β-tubulin residues 
that modify the binding site [40, 72, 80], binding of MT-regulatory proteins [72], decrease of 
CDK (cyclin-dependent kinase) level, which cause a mitotic delay, overexpression of the 
microtubule associated protein tau mRNA and decrease in affinity of targeted drugs to the 
target (MTs) [40]. Anticancer drug resistance can also be related with other tubulin forms or 
other proteins in the centrosome in interphase or mitotic spindle poles in mitosis, but it 
clearly exists a need for much more research in this field [72]. The use of cancer cell lines for 
resistance/sensitivity studies is imperative, neverless, their poor characterization can lead to 
problems in the data interpretation. Nakayama and colleagues (2009) used breast cancer cell 
lines and xenograft models for the discovery of characteristics related with the sensitivity or 
resistance to paclitaxel. They deduced that the in vitro response to paclitaxel do not predict 
exactly the sensitivity to this drug in vivo (80%) [40]. However they used cancer cell lines like 
MCF7 that were established many years ago and need to be properly characterized, as 
already mentioned. An altered response to certain compounds can also occur by the clonal 
variants of cancer cell lines and the xenograft may exhibit a cellular environment that can 
modify the response [5]. More importantly, they concluded that the decrease of CDK1 
(cyclin-dependent kinase) is related with tumour cells’ resistance and that the increase of 
CDK2 is required for the increase of sensitivity. Thus, analysis of CDKs can predict clinically 
the sensitivity to paclitaxel [40]. Nakatsu and colleagues (2005) also used cancer cell lines for 
the identification of genes related with the sensitivity to paclitaxel (and other anticancer 
drugs). With their work, they found that the genes related with tubulin-binder and 
cytoskeleton-related as VIL2 (encoding ezrin) and ACTB (encoding h-actin) are related with 
the paclitaxel chemosensitivity, proposing these genes as predictor markers for anticancer 
drug efficacy [10]. In other work using cancer cell lines as models for paclitaxel resistance 
analysis, the cells were transformed into resistant by the progressive increase of the drug 
[80]. The profiling of cancer cell lines paclitaxel-resistants’ can allow the identification of 
resistance mechanisms [72].  
The knowledge of the specific composition of MT regulatory proteins or other regulatory 
proteins and different tubulin isotypes of cancer cell lines, and the way these interfere with 
the effectiveness of MT-targeted drugs, can be helpful for a better clinical application of 
these drugs and for the development of molecularly targeted drugs by its combination, 
overcoming the MDR [72, 83] and the side effects as neuropathy. For this, it is essential to 
understand the exact mechanism of action of antimitotic drugs, the relation of drug-induced 
mitotic block and cell death and the interaction of these drugs with centrosomes and the 
mitotic spindle pole (where other types of tubulin exist). Another question is why some 
antimitotic drugs as taxanes are efficient in some tumours as breast, ovarian and lung, but 
are inefficient in kidney, colon cancers, sarcomas and others of the same group of MT-
targeted drugs, like Vinca alkaloids are more efficient in hematologic malignancies and 
ineffective against solid tumours [72]. 
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The use of different types of well-characterized cancer cell lines at the genome and 
methylome levels can allow the study of the mechanisms of antimitotic drugs and if the 
mechanism of resistance are related with the methylation pattern. Thus, the characterization 
of cancer cell lines at the DNA methylation level and the combination of these antimitotic 
drugs with 5'AZA may be a straightforward strategy to understand the mechanism of action 
of such drugs and testing their combination.  
The profiling of cancer cell lines at the DNA methylation level is also important for the 
prediction of chemotherapeutic response [51]. Hypermethylation of the promoter regions of 
some genes, as of the DNA repair gene MGMT that happens in glioma, increases the 
sensitivity to alkylating agents as carmustine (BiCNU®) [51, 54]. Arnold and colleagues 
(2003) analysed hypermethylated colorectal cancer cell lines after exposure to a 
demethylating drug and found that the hypermethylation of the gene MLH1 was reverted 
by these type of drugs, decreasing the resistance to the anticancer drug fluorouracil (5-FU) 
[84]. Shen and colleagues (2007) in a work performed in the NCI60 panel of cancer cell lines 
were able to elaborate a list of methylation markers to predict the anticancer drug response 
[63]. These works highlight the fact that methylation/demethylation studies performed in 
cell lines definitely provide a powerful system model for the definition of new candidate 
strategies to overcome the problem of drug resistance in the treatment of cancer. The exact 
mechanism of action of demethylating agents or the patterns of resistance and sensitivity are 
unclear and it is extremely important to understand the molecular changes induced by these 
drugs to increase their effectiveness [69, 85].   
As already mentioned, in cell lines, demethylating drugs, as azacytidine and decitabine 
cause global demethylation of DNA by the inhibition of DNMTs, reverting the gene 
silencing induced by hypermethylation [51-53, 69]. The use of such demethylating drugs can 
cause inhibition of cell proliferation and G2 arrest [85] but can also lead to the 
reestablishment of proliferation control and apoptotic sensitivity [69]. In spite of the 
oversight of information about the azanucleosides, these anticancer drugs are currently used 
in the treatment of myelodysplastic syndrome (MDS) and other types of leukaemia [51-53, 
85]. However, it is essential an improved knowledge on the mechanisms of action of these 
epigenetic drugs at the molecular level and the cellular pathways that they influence, as well 
as the identification and validation of response predictor markers [69] for the application of 
these drugs in more cancer types and with conjugation with other anticancer drugs.  
The development of treatments that accomplish a specific reversion of DNA methylation 
modifications without interfering in the normal epigenetic events required for the cellular 
function [53] has stimulated the research of other inhibitors of DNMTs [51, 53]. The use of 
cancer cell lines allows the testing of other potential demethylating agents with the purpose 
to observe the effect of such drugs in tumour cells. Other demethylating agents as 
hydralazine and procainamide (cardiovascular drugs) in breast cancer cell lines cause 
demethylation and expression reestablishment of ER, RARβ, and P16INK4a [86]. Alternative 
inhibitors of DNMTs that have focused the researchers attention are DNMT antisense and 
siRNA [51, 53]. It was proved in colon and bladder cancer cell lines that an antisense 
oligodeoxynucleotide as MG98 is a DNMT1 antisense inhibitor that cleaves its mRNA 
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resulting in the demethylation and replacement of the normal expression of P16INK4a [87]. 
The siRNA can be designed as an inhibitor of DNMTs, but can also be used as a target for 
the proteins involved in the regulation of the methylated gene [51].  
So, the characterization of both the genome and methylome of cancer cell lines allows the 
discovery of targets to anticancer drugs and to create more targeted drugs for certain types 
of cancer, providing the development of new therapies [35], as the use of siRNA, or the 
combination of new or already existing ones. 
The use of siRNA in cancer therapy is a new research field and promises to silence critical 
cancer genes, as oncogenes [88]. The use of cell lines was essential for the discovery of this 
potential specific gene cancer therapy by the suppression of expression of these genes [89] 
and blocking of the biological processes that comprise the hallmarks of cancer [88]. The 
major problem of using siRNAs as anticancer therapeutics does not rely in their design or 
mechanism of action, but in their delivery. To overcome this problem, nanoparticles [88, 90] 
(lipid, organic or inorganic) have been used for degradation protection, facilitating the cell 
transfection and allowing the delivery in the right place [88]. Presently, some siRNAs that 
use nanoparticles as delivery vehicles are in clinical trials [88, 90], however, at the moment, 
none have been approved [88]. A siRNA against PLK1 is in conclusion of phase I of clinical 
trials in different types of cancer [88] (http://www.clinicaltrials.gov/ct2/show/ 
record/NCT01437007) and good results are expected because of the importance  
of this protein in mitosis and in the maintenance of genome stability [82]. Another siRNA 
that is in a clinical trial phase with successful results is a siRNA for the depletion  
of M2 subunit of Ribonuclease reductase (RRM2) in solid tumours [88, 90, 91] 
(http://www.clinicaltrials.gov/ct2/show/NCT00689065), decreasing the proliferation of 
cancer cells in vitro and in vivo [91]. The mutation of K-RAS is associated with one third of 
the human cancers and is a resistance factor of many cancers to therapy. The depletion of 
this protein is an excellent target for cancer treatment, leading cancer cells to apoptosis. A 
phase I of a clinical trial is being carried out for this target (siG12D LODER (Local Drug 
EluteR)) in patients with pancreas adenocarcinoma, since most of the pancreas cancer cells 
have K-RAS mutated [88] (http://www.clinicaltrials.gov/ct2/show/NCT01188785). Although 
none siRNAs are yet available for cancer treatment, it is expected that in the near future they 
could be used as cancer therapeutic agents.   
The identification of more cancer-type related genes, DNA methylation profiles and altered 
cellular pathways in cancer cell lines is crucial for understanding drugs’ mechanisms of 
action and its resistance patterns, and for developing and testing new targeted anticancer 
drugs. 
5. Conclusion 
In conclusion, well-characterized cancer cell lines at the molecular level are excellent models 
for the study of the altered cellular pathways, critical genes and methylome in cancer, and 
for anticancer drug testing. Although we have now a reasonable knowledge of the genome 
of this model, we are still in the beginning of knowing its methylome. The recent 
The Importance of Cancer Cell Lines as in vitro Models in  
Cancer Methylome Analysis and Anticancer Drugs Testing 159 
technologies are very useful for this molecular profiling, which is absolutely required before 
the use of any cancer cell line in a research program. The study of the methylome in cancer 
using cell models is essential, since epigenetic modifications can occur early in oncogenesis, 
being the DNA methylation pattern a good target for chemotherapy. The molecular cancer 
cell lines profiling is also essential for the development of new anticancer drugs and for 
understanding the mechanism of action and the patterns involved in cell resistance to 
chemotherapeutics already used in the treatment of cancer. Moreover, cancer cell lines 
profiling can be a powerful tool for the identification of genes’ alterations or pathways 
cancer-related and for the discovery of putative drug targets.  
Nomenclature 
In the present work the nomenclature for human genes and proteins was the one 
recommended by HGNC (HUGO Gene Nomenclature Committee). For mouse and rat, we 
followed the one suggested by MGI (Mouse Genome Informatics).   
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